Understanding the emergence and evolution of artemisinin resistance in Rwanda
Artemisinin Resistance in Africa: its emergence and evolution in Rwanda
This study is looking into how some malaria parasites in Rwanda are becoming resistant to a key treatment, focusing on a specific gene change that makes it harder to clear the infection, so we can better understand how this might affect the medicines used to treat malaria and help keep them working well for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brown University NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project ID | NIH-10908274 on NIH RePORTER |
What this research studies
This research investigates the emergence of artemisinin resistance in Rwanda, focusing on the mutation of the K13 gene associated with delayed parasite clearance in malaria patients. By analyzing the spread and biological factors influencing this resistance, the study aims to understand how it may impact the effectiveness of current antimalarial treatments. The research employs genetic assays and epidemiological methods to track the mutation's origin and its potential spread across Africa. This knowledge is crucial for developing effective strategies to combat malaria and ensure the continued efficacy of artemisinin combination therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals in Rwanda who are diagnosed with Plasmodium falciparum malaria and may exhibit delayed parasite clearance.
Not a fit: Patients with malaria caused by other species or those who do not reside in regions affected by artemisinin resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for managing and treating malaria, potentially saving lives and reducing morbidity in affected populations.
How similar studies have performed: Previous research has shown significant success in understanding drug resistance in malaria, particularly in Asia, but this study addresses a novel situation in Africa that has not been extensively explored.
Where this research is happening
Providence, United States
- Brown University — Providence, United States (Active)
Researchers
- Principal investigator: Bailey, Jeffrey a. — Brown University
- Study coordinator: Bailey, Jeffrey a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.